![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Shire | LSE:SHP | London | Ordinary Share | JE00B2QKY057 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 4,690.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
24/4/2018 11:50 | Bloomberg... Takeda Near Preliminary Agreement to Acquire Shire ++ Companies could announce tentative accord as early as Tuesday ++ Talks revolve around improved bid, including cash portion Takeda Pharmaceutical Co. is nearing a preliminary agreement to acquire Shire Plc after the Japanese drugmaker sweetened its roughly $60 billion bid for the biotechnology company, according to people with knowledge of the matter. The two companies have been working on a tentative agreement on price and may announce a preliminary accord as early as Tuesday, the people said, declining to be identified as the discussions are confidential. Under U.K. takeover rules, Takeda must announce a firm offer or abandon its pursuit by Wednesday afternoon. The companies may seek an extension from authorities to finalize talks, the people said. Discussions this week have revolved around an improved offer, including a possible increase in the cash component, the people said. The exact terms of the offer couldn’t be immediately learned. Talks may still be delayed or fall apart, they said. Representatives for Takeda and Shire declined to comment. | ![]() philanderer | |
24/4/2018 11:44 | GSK is my no 1 stock in my portfolio, nice quarterly dividend at an attractive yield still, better than down at el banco and with capital growth prospects. | ![]() ny boy | |
24/4/2018 11:36 | Where would one invest SHP money? | ![]() demo trader | |
24/4/2018 11:33 | Yep. It would appear that way but a little odd the share price is still only just over £40 so far. These people in the know, you could make a fortune out of such early leaky rumours! ATB, Scfc | scfc1 | |
24/4/2018 11:32 | The announcement will be timed for the US audience. | ![]() romeike | |
24/4/2018 11:27 | When will an announcement be made I wonder?At 1200 - when the 2 minute auction happens?Or 2100 when US, UK and Japanesee matkets are all closed?Or will we be shafted by an announcement after 1630 that spikes the price only for it to fall back somewhat after hours? | ![]() paa65 | |
24/4/2018 11:27 | Has to be a period for due diligence as well. | ![]() philanderer | |
24/4/2018 11:25 | Patience is the game.....the share price has to get to within 90%+ of the bid price to flush out ´smart ´ sellers = 4302 pennies, if the 4780 figure is correct... | ![]() marcela9 | |
24/4/2018 11:23 | A formal bid now seems certain if the rumours can be believed and yet it is struggling to stay over £40. If anything it is more likely there will be a penalty clause for if Takeda pull out once a formal bid is accepted. With AbbVie I believe the penalty clause was as high as $2 Billion. | ![]() romeike | |
24/4/2018 11:17 | There were reasons for SHIRE to drop from 5900p + to below 3000p. There may be penalty clause by Takeda if Shire agrees the bid ( not to agree with other bidders ). I see SHP to reach 4400p to 4500p soon, BIG IMO. | ![]() demo trader | |
24/4/2018 11:13 | Agree with that guys | ![]() philanderer | |
24/4/2018 11:13 | Hope so because much as ~£48 is okay I think it is cheap cheap and I previously would have thought £54 would have been the minimum the board would accept. | ![]() romeike | |
24/4/2018 11:08 | Billy, yes, if bid accepted, fomo will set in. Will be last chance to secure Shire's pipeline. | ![]() ruethewhirl | |
24/4/2018 10:55 | If this gets accepted it may well prompt other bidders. | billytkid2 | |
24/4/2018 10:51 | rrb <- bad advice for people with large holdings - most of the large US funds holding Shire also appear to hold similar levels of Takeda stock. You say take £44 instead of £48 - just how far are you expecting Takeda to drop! 3% yield not bad while you reduce holding over time to limit gains tax. | ![]() romeike | |
24/4/2018 10:47 | DIVIDEND in kitty. They paid out 21 pence per share at converted exchange rate. Small change if price goes to around £44 | scothernman | |
24/4/2018 10:47 | Bid value £47.80 but half of that in takeda shares so actually unlikely shares will trade anywhere near that. There are plenty of funds (esp uk) who won’t be mandated to hold Japanese equity. And even more that won’t like the idea of holding shares in a heavily indebted Japanese pharma company. So if it gets anywhere near 44-45, take your money and run! | ![]() rrb | |
24/4/2018 10:30 | Yep, in my Selftrade account early this morning. | ![]() philanderer | |
24/4/2018 10:29 | have holders received the dividend payment, checked earlier, wasn’t showing? | ![]() ny boy | |
24/4/2018 10:27 | Tks, I will just hold. Have been buying GSK for a few years, adding on pull backs, I like the quarterly divis, still a decent annual yield 4%+ | ![]() ny boy | |
24/4/2018 10:19 | With 920m shares a bid of 44Bn equals £47.80 per share | ![]() paa65 | |
24/4/2018 10:17 | Doubt it will trade through ....... unless mkt truly believes rivals reckoned on this deal being dead in the water ..... interesting times | ![]() soundbuy | |
24/4/2018 10:15 | When Abbvie bid for Shire the share price at one point exceeded the bid price. I don't expect that to happen here. It seems likely that the formal bid will be higher than the last indicative offer of £47. I think punters wanting out early will take up to £44. Personally I will hold for the full value as it suits me for tax purposes. | ![]() romeike | |
24/4/2018 10:12 | What level are we expecting the share price to reach? | ![]() ny boy |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions